BME Seminar w/ Dr. Jeffrey Weitz
02/02/17 Portland, Ore.
Factor XI and XII as targets for new anticoagulants
Presenter: Jeffrey I. Weitz, MD - Prof. of Medicine and Biochemistry and Biomedical Sciences, McMaster University
Executive Director, Thrombosis and Atherosclerosis Research Institute
Time: Thursday, February 02 at 3:00
Location: CHH, 3rd Floor Conference Room 1A&B
Abstract: There is mounting evidence that factor XII and factor XI, components of the intrinsic pathway of coagulation, are essential for thrombus stabilization and growth. In contrast, factor XII is dispensable for hemostasis and factor XI plays only a minor part. Therefore, factor XII and factor XI have emerged as promising targets for new anticoagulants that may be safer than those that are currently available. These new anticoagulants include antisense oligonucleotides that lower factor XII or factor XI levels, antibodies against factor XII or factor XI, and small molecule inhibitors. Studies are needed to determine whether factor XI or factor XII is the better target, and to compare the efficacy and safety of these new strategies with current standards of care for prevention or treatment of thrombosis.